NewsBenzingaHC Wainwright & Co. mantiene il giudizio Buy su Candel Therapeutics, abbassa il prezzo obiettivo a 18 $ HC Wainwright & Co. mantiene il giudizio Buy su Candel Therapeutics, abbassa il prezzo obiettivo a 18 $ Benzinga 2026.11.13 18:28 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Monster Beverage with Outperform Rating Druckenmiller Buys Miners, Warns '27 Could Be 'Disappointing' Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42 Wolfe Research Initiates Coverage On PepsiCo with Peer Perform Rating BTIG Reiterates Neutral on FuboTVto Neutral Bitcoin Erases Summer Rally as ETF Outflows Persist
Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42